Consumers' perceptions about risk of and access to nonprescription medications

Journal of the American Pharmacists Association

Volumn 45, Issue 3, 2005, Pages 363-370

  Alexander, G Caleb ^a,b,c   Mohajir, Nadiah ^e   Meltzer, David O ^d  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

^d UNIVERSITY OF CHICAGO   (United States)

^e NONE

Author keywords

Consumer sovereignty; Drug safety; Drug related problems; Regulation of pharmaceuticals; Risk nonprescription medications

Indexed keywords

NON PRESCRIPTION DRUG;

ACADEMIC ACHIEVEMENT; CONSUMER; CONSUMER ATTITUDE; CONSUMER HEALTH INFORMATION; CONTROLLED STUDY; DRUG SAFETY; HEALTH SURVEY; HUMAN; HUMAN EXPERIMENT; MEDICAL CARE; MULTIVARIATE ANALYSIS; PATIENT SAFETY; PRESCRIPTION; REVIEW; RISK FACTOR; SELF REPORT; UNITED STATES; ADULT; ARTICLE; ATTITUDE TO HEALTH; CROSS-SECTIONAL STUDY; FEMALE; HEARTBURN; HYPERTENSION; INFORMATION PROCESSING; MALE; MIDDLE AGED; SOCIAL CLASS;

ADULT; ATTITUDE TO HEALTH; CONSUMER SATISFACTION; CROSS-SECTIONAL STUDIES; DATA COLLECTION; DRUGS, NON-PRESCRIPTION; FEMALE; HEARTBURN; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; MIDWESTERN UNITED STATES; RISK FACTORS; SOCIAL CLASS;

EID: 22144483434     PISSN: 15443191     EISSN: 15443450     Source Type: Journal    
DOI: 10.1331/1544345054003868     Document Type: Article

References (24)

1. Brass E. Changing the status of drugs from prescription to over-the-counter availability. N Engl J Med. 2001;345:810-6.
2. Newton G, Popovich NG, Pray WS. Rx-to-OTC switches: from prescription to self-care. J Am Pharm Assoc. 1996;NS36:488-95.
3. Temin P. Costs and benefits in switching from Rx to OTC. J Health Econ. 1983;2:187-205.
4. Arrow KJ. Uncertainty and the welfare economics of medical care. Am Econ Rev. 1963;53:141-9.
5. Quill T, Brody H. Physician recommendations and patient autonomy: finding a balance between physician power and patient choice. Ann Intern Med. 1996;125:763-9.
6. Bond C, Bradley C. Over the counter drugs: the interface between the community pharmacist and patients. BMJ. 1996;312:758-60.
7. McCallian DJ, Cheigh NH. The pharmacist's role in self-care. J Am Pharm Assoc. 2002;42(5 suppl 1):S40-S41.
8. Amsler MR, Murray MD, Tierney WM, et al. Pharmaceutical care in chain pharmacies: beliefs and attitudes of pharmacists and patients. J Am Pharm Assoc. 2001;41:850-5.
9. Rheinstein PH. Criteria used by the FDA to determine what classes of drugs are suitable switch candidates. Drug Info J. 1985;19:139-42.
10. Kranz H. Over-the-counter drugs: the issues. Drug Safety. 1990;5:120-5.
11. Hughes GF, McElnay MC, Hughes CM, McKenna P. Abuse/misuse of non-prescription drugs. Pharm World Sci. 1999;21:251-5.
12. Shi CW, Asch SM, Fielder E, et al. Usage patterns of over-the-counter phenazopyridine (pyridium). J Gen Intern Med. 2003;18:281-7.
13. Zhang J, Yu KF. What s the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes. JAMA. 1998;280:1690-1.
14. Ubel PA. The challenge of measuring community values in ways appro-priate for setting health care priorities. Kennedy Inst Ethics J. 1999;9:263-84.
15. Ferraz MB, Pereira RB, Paiva JGA, et al. Availability of over-the-counter drugs for arthritis in Sao Paulo, Brazil. Soc Sci Med. 1996;42:1129-31.
16. Lipsky MS, Waters T. The "prescription-to-OTC switch" movement: its effects on antifungal vaginitis preparations. Arch Fam Med. 1999;8:297-300.
17. Kravitz RL, Bell RA, Azari R, et al. Direct observation of requests for clinical services in office practice: what do patients want and do they get it? Arch Intern Med. 2003;163:1673-81.
18. Taylor J, Berger B, Anderson-Harper H, Grimley D. Pharmacists' readiness to assess consumers' over-the-counter product selections. J Am Pharm Assoc. 2000;40:487-94.
19. Craig JA, Eves GB. Minimizing drug misuse among elders: a proposal. Public Health Rep. 1987;102:86-90.
20. Bradshaw SJ, Doucette WR. Community pharmacists as patient advocates: physician attitudes. J Am Pharm Assoc. 1998;38:598-602.
21. Morris LA, Halperin JA. Effects of written drug information on patient knowledge and compliance: a literature review. Am J Public Health. 1979;69:47-52.
22. Healy JW. What is hazardous? What is safe? Environ Health Perspect. 1978;27:317-21.
23. Marris C, Langford I, Saunderson T, O'Riordan T. Exploring the "psychometric paradigm": comparisons between aggregate and individual analyses. Risk Anal. 1997;17:303-12.
24. Freudenburg WR, Rursch JA. The risks of "putting the numbers in context": a cautionary tale. Risk Anal. 1994;14:949-58.